PINS is the leader in China’s medical neural interface market and a driving force harnessing neurotechnology to chart the frontier of silicon-carbon intelligence.

Our journey began with a simple question: “How would you build this product if your loved ones were the ones using it?” That question established our enduring ethos, “Loving Others as Ourselves ” and guides every stage of our work, from product design and clinical trials to manufacturing and quality control. Progress, for us, is measured in restored autonomy and changed lives: a Parkinson’s patient restoring motor capabilities, a child with epilepsy finding prolonged relief from debilitating seizures, or a paralyzed individual taking a courageous step forward through our technology.

Since our inception in 2008, we have achieved a series of industry-defining milestones that have shaped the trajectory of China’s medical neural interface industry:

• National Distinctions. In 2013, we secured the first NMPA approval for a domestically developed DBS system. In 2018, our project on “Key Technologies, Systems and Clinical Applications of DBS” received the First-Class National Science and Technology Progress  Award (國家科學技術進步獎一等獎) from the State Council of the PRC。

• Technological Superiority. Our proprietary full-stack technology architecture powers high-fidelity neural gateway, AI-powered signal decoding, adaptive actuation and longterm active implant engineering within a single stack, enabling realtime neural activity monitoring synchronized with adaptive therapeutic output across our 4S product matrix and beyond.

• Institutional Stewardship. In 2016, we cofounded the National Engineering Research Center for Neuromodulation with Tsinghua University and Beijing Tiantan Hospital, We also established the Global Neuromodulation Award in collaboration with the Science journal to honor pioneers and advance global technical standards.

How We Innovate

Guided by our mission to create life- changing value for patients, we have deepened our technical capabilities to target critical unmet patient needs by broadening our neuromodulation categories, expanding our clinical indications and building a product portfolio that spans the central and peripheral nervous systems. Our neural interface matrix comprises six neuromodulation categories: our commercially established 4S product matrix, and two pipeline programs targeting emerging clinical indications.

WHY WE LEAD

We are committed to creating life-changing value for patients. By standing alongside patients and physicians, we find real medical needs. Our full-stack technologies let us engineer precise solutions. Continuous R&D keeps our products advancing. We manufacture our own products, so quality and reliability are never outsourced. Strong commercialization brings our treatments within reach of more patients. Each strength reinforces the others, and the result compounds: the more patients we help, the stronger the virtuous cycle becomes. The strengths outlined below are what that integrated approach produces.

Full-Stack Technologies

We have proprietary full-stack neural interface technologies to translate clinical understanding into products that can operate safely and effectively inside the human body for decades. These technologies cover the following four distinct areas: high-fidelity neural gateway, AI-powered signal decoding, adaptive actuation and long-term active implant engineering. Because we have full-stack technologies, a breakthrough in any layer flows immediately into every product line, shortening the path from early-stage research to an approved product that reaches patients.

• High-Fidelity Neural Gateway. Our leads form the physical bridge between the human nervous system and our products, simultaneously reading neural signals and delivering targeted therapy. Building this bridge requires leads that are safe for long-term contact with living tissue, precisely shaped for each anatomical target, and securely anchored in place. Our lead portfolio is commercially proven across our 4S product matrix, including cylindrical leads for DBS, helical leads for VNS, tined leads for SNM and paddle leads for SCS. Beyond standard stimulation, we have developed three differentiated capabilities:

• AI-Powered Signal Decoding. The effectiveness of any neural interface depends on how accurately it can interpret what is happening inside the patient’s nervous system. Our signal processing engine pairs low-power acquisition chips with machine learning and deep neural network algorithms that identify neural patterns and determine the appropriate therapeutic response in real time. This combination addresses the core technical constraints of bidirectional interaction at the implant level: filtering out noise, conserving battery power and processing signals instantly. This decoding technology enables our products to autonomously recognize complex physiological states and supports the advanced signal integration required to restore complex motor function through next-generation BSI and exoskeleton systems.

• Adaptive Actuation. The integration of neural encoding and closed-loop adaptive control forms the functional core of bidirectional neural interfaces. Our stimulation encoding protocols have been validated over multiple years across our product portfolio, supporting variable frequency and complex stimulation sequences. We have deployed closed-loop stimulation technology in multiple product lines, each responding automatically upon detecting neural or physiological biomarkers. In DBS, our closed-loop technology continuously decodes neural biomarkers and adjusts stimulation parameters in response to each patient’s detected physiological state. In VNS, our ECG-based G114R system automatically modifies stimulation in response to cardiac biomarkers associated with seizure onset. We are also advancing adaptive encoding driven by ECAP signal detection to establish closed-loop standards across our SCS product line.

• Long-Term Active Implant Engineering. Our products must remain safe and functional inside the body for decades. Our product reliability is built in from the start: materials, structural joints and seals are tested against the device’s full expected lifetime before it ever reaches a patient. Our compact antenna designs  simplify  post-surgical  wireless  programming,  while  advances  in  wireless fast-charging and high-density component integration reduce the burden on patients and maintain long-term product reliability.